Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Endocrine and neuroendocrine tumours

3074 - Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in a Phase 3 Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC)


11 Sep 2017


Endocrine and neuroendocrine tumours


Cytotoxic Therapy;  Thyroid Cancer


Makoto Tahara


Annals of Oncology (2017) 28 (suppl_5): v142-v157. 10.1093/annonc/mdx368


M. Tahara1, M.S. Brose2, L. Wirth3, T. Suzuki4, K. Fujino4, N. Batty5, C. Dutcus6, A. Gianoukakis7

Author affiliations

  • 1 Division Of Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 2 The Thyroid Cancer Therapeutics Program Department Of Otorhinolaryngology: Head And Neck Surgery, Abramson Cancer Center, University of Pennsylvania, 19104 - Philadelphia/US
  • 3 Hematology/oncology, Massachusetts General Hospital, Harvard University, 2114 - Boston/US
  • 4 Eisai Co., Ltd, Tokyo/JP
  • 5 Eisai, Inc, Woodcliff Lake/US
  • 6 Eisai, Inc, NJ 07677 - Woodcliff Lake/US
  • 7 Endocrinology Fellowship Program, UCLA School of Medicine, Torrance/US


Abstract 3074


LEN prolonged progression-free survival (PFS) in pts with RR-DTC in the SELECT trial, and efficacy was maintained in all subgroups. Toxicity was manageable with dose modifications, but whether a longer period of dose interruption might impact the efficacy of LEN was unclear.


In SELECT, pts were randomized 2:1 to receive LEN 24 mg/day or placebo. Pts assigned to LEN were divided into 2 groups: pts with duration of dose interruption


Of 261 LEN-treated pts, there were 134 in group A and 127 in group B. Differences in pt characteristics between groups (A and B) were, respectively: age (>65 years, 33% and 49%), race (Asian, 10% and 25%), and ECOG performance status (0, 64% and 46%). Median duration of dose interruption was 19 days (range: 0–63) and 61 days (range: 2–266) in groups A and B, respectively. Median PFS was not reached (hazard ratio [HR] to placebo: 0.14; 95% CI: 0.09–0.20, P 


Longer duration of dose interruption may negatively affect the potential efficacy of LEN. Management of toxicities is essential to avoid long dose interruption. Differences in pt characteristics might confound the results. However, in this analysis LEN achieved improved PFS and ORR compared to placebo, regardless of length of dose interruption.

Clinical trial identification


Legal entity responsible for the study

Eisai Inc


Eisai Inc


M. Tahara: Grants and personal fees from Eisai during the conduct of the study and personal fees from Merck Serono, BMS, and Bayer outside the submitted work. M.S. Brose: Grants from Eisai during the conduct of the study. Grants and personal fees from Bayer HealthCare Pharmaceuticals, Exelixis, and Onyx. Grants from Novartis and Roche/Genentech outside the submitted work. L. Wirth: Personal fees from Eisai and Novartis outside the submitted work. T. Suzuki, K. Fujino: Employee of Eisai Co., Ltd. N. Batty, C. Dutcus: Employee of Eisai Inc. A. Gianoukakis: Grants and nonfinancial support from Eisai during the conduct of the study.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.